Hikma Pharmaceuticals (HIK)

 

HIK Share PerformanceMore

52 week high2,346.0 16/03/17
52 week low906.5 14/11/17
52 week change -933.0 (-48.03%)
4 week volume11,661,998 27/12/17

Latest NewsMore

Hikma appoints chief scientific officer and head of R&D

Hikma Pharmaceuticals has appointed Surendera Tyagi as group chief scientific officer and global head of research and d...

Hikma Appoints Dr. Surendera Tyagi

RNS Number: 8062B Hikma Pharmaceuticals Plc 15 January 2018 PRESS RELEASE Hikma Appoints Dr. Surendera Tyagi as Group Chief Scientific Officer and Global Head of R&D London, 15 January 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable), today announc...

Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLC

Jefferies International today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to underperfor...

Total Voting Rights

RNS Number: 9826A Hikma Pharmaceuticals Plc 04 January 2018 Hikma Pharmaceuticals PLC Total Voting Rights and Capital LONDON, 4 January 2018 - In accordance with the UK Financial Conduct Authority's (the " FCA ") DTR 5.6.1, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 31 D...

Hikma reaches licensing agreement with Celltrion

RNS Number: 6681Z Hikma Pharmaceuticals Plc 19 December 2017 PRESS RELEASE Hikma reaches licensing agreement with Celltrion for third biosimilar product in the Middle East and North Africa London, 19 December 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) ...

Hikma- Dihydroergotamine Mesylate Injection, USP

RNS Number: 1516Z Hikma Pharmaceuticals Plc 13 December 2017 PRESS RELEASE Hikma launches Dihydroergotamine Mesylate Injection , USP London, 13 December 2017 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that its wholly-owned US subsidiary ...

Holding(s) in Company

RNS Number: 0874Z Hikma Pharmaceuticals Plc 12 December 2017 TR-1: S tandard form for notification of major holdings LONDON, 12 December 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75) , the fast-growing multinational pharmaceuticals group, announces as follows: NOTIFICATION OF MAJOR HOL...

Holding(s) in Company

RNS Number: 9510Y Hikma Pharmaceuticals Plc 11 December 2017 TR-1: S tandard form for notification of major holdings LONDON, 11 December 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75) , the fast-growing multinational pharmaceuticals group, announces as follows: NOTIFICATION OF MAJOR HOLD...

Fundamental DataMore

P/E ratio15.184
EPS66.5
Dividend yield3.268 %

Latest discussion posts More

  • Here we go again

    They may have been oversold, but it is all one way traffic at the minute. The MM will have their fun, suck a few more in, pull the plug, repeat. I can see no imperative to jump ...
    6-Dec-2017
    Ravinell
  • Re: P/E 10; strong balance sheet

    We all know the market is incredibly rogue, corrupt and a short sellers dream. BTW how many of you have notified the FCA's market abuse and intelligence teams regarding this ...
    14-Nov-2017
    Thedarkkn1ght
  • Re: P/E 10; strong balance sheet

    I thought this morning's news was positive, and a broker update had a target price about 50% up from here, but when the market is out of love with a share.......
    14-Nov-2017
    Hardboy

Users' HoldingsMore

Users who hold Hikma Pharmaceuticals also hold..

Codes & Symbols

ISINGB00B0LCW083
SymbolsHIK, LSE:HIK, HIK.L, HIK:LN, LON:HIK, XLON:HIK

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account